Most people
are not a fit.
Neurologic MSC therapy is an evaluation-first program. We decline more cases than we treat. The honest filter is here before you fly, before you pay, and before hope gets in front of evidence.
About half of inquiries are declined with reasons and, where appropriate, a referral.
Indication with biologic plausibility, imaging that matches, and realistic expectations.
We do not enroll families in expensive therapy when the biologic case isn't there.
Why we're
slow here.
Neurologic disease varies enormously in mechanism, time course, and biologic targetability. MSC therapy has genuine case reports and reasonable rationale in narrow indications, and genuinely no business being offered in broad ones.
The families most likely to reach us have already heard every version of hope and every version of no. Our job isn't to add another "maybe." It's to read the case honestly and say yes, no, or not yet, with reasons.
If your case has a plausible indication and reasonable imaging, we'll evaluate carefully. If it doesn't, we'll decline and tell you why.
We don't market "stem cells for Alzheimer's" or "stem cells for autism." Those positions exist in the regenerative industry, and they are not where the biology lands. We'll be direct about what we don't treat.
Where the biology
can reach.
Peripheral neuropathy
Diabetic, chemotherapy-induced, or idiopathic peripheral neuropathy with preserved nerve structure on imaging.
- Imaging confirmed
- Established diagnosis
- Reasonable expectations
Select post-injury cases
Post-concussion syndrome, select post-stroke recovery, and certain post-surgical neurologic residuals, case-by-case only.
- Time from event matters
- Imaging review essential
- Decline more than we accept
Autoimmune-adjacent
Select cases with demonstrated inflammatory component where systemic immunomodulation has rationale.
- Documented inflammatory markers
- Prior therapy trials documented
- Realistic goals
ALS, palliative intent
Early-to-mid ALS, accepted for quality-of-life support only. We are explicit up front: this is palliative, not disease-modifying. MSC therapy does not cure ALS.
- Early-to-mid stage only
- Quality-of-life goals
- Co-management with treating neurologist
What we
decline.
Declining cases is how we stay honest. Families with these profiles are frequently told "yes" by clinics outside the United States. Some of those clinics are well-intentioned. Many aren't. The outcomes, broadly, do not support the optimism.
Neurodegenerative disease (late stage)
Late-stage ALS, Parkinson's, Huntington's, and similar with significant structural loss. The biology cannot reach what's gone. Early-to-mid ALS is considered separately for quality-of-life support only, see candidate profiles.
Autism spectrum disorder
No biologic rationale. We do not offer MSC therapy for autism. Any clinic doing so is outside the science.
Dementia & Alzheimer's
Systemic MSC therapy has not shown meaningful disease modification in dementia. We decline these cases.
Pediatric cerebral palsy
Structural neurologic injury in a developing brain is not a case where current MSC therapy has demonstrated durable benefit.
How a neurologic
case is evaluated.
Written submission
Diagnosis, imaging, medication history, prior therapy trials, goals. Submitted in writing before any call.
Physician review
Attending reviews the written submission and imaging against established neurologic criteria. Decision may land here.
Conversation
If the profile merits further evaluation, an extended call with the physician. Questions both ways.
Accept, decline, or defer
Accept with a written plan. Decline with reasons and referrals where appropriate. Defer pending additional imaging or trials.
Candidacy
questions.
Q.01My neurologist said stem cells won't help. Why submit anyway?
Q.02Why decline cases other clinics accept?
Q.03Is there any version of stem cell therapy that helps my condition?
Keep
reading.
Submit for
honest evaluation.
The written intake is the first filter. It's slow by design, the purpose is to decide well, not to fill a schedule.